Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fizazi, K.
Right arrow Articles by Chen, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fizazi, K.
Right arrow Articles by Chen, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1295, 2004
© 2004 European Society for Medical Oncology

Oxaliplatin in non-seminomatous germ-cell tumors

The first 10% of the full text of this article appears below.

Recently, Kollmannsberger et al. [1Go] reported the final results of a phase II trial of oxaliplatin as a single agent in patients with relapsed or refractory non-seminomatous germ-cell tumors (NSGCT) treated from 1998 to 2001. The authors concluded that oxaliplatin is an active agent and . . . [Full Text of this Article]

K. Fizazi1,*, S. Culine2 and I. Chen3

1 Department of Medicine, Institut Gustave Roussy, Villejuif; 2 Centre Val d'Aurelle, Montpellier, France 3 Department of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA

* Email: fizazi@igr.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Theodore, C. Chevreau, Y. Yataqhene, K. Fizazi, J. -P. Delord, J. -P. Lotz, L. Geoffrois, P. Kerbrat, V. Bui, and A. Flechon
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
Ann. Onc., August 1, 2008; 19(8): 1465 - 1469.
[Abstract] [Full Text] [PDF]